Search alternatives:
significant compared » significant component (Expand Search), significantly impaired (Expand Search), significant impact (Expand Search)
compared diseases » complex disease (Expand Search)
side decrease » sizes decrease (Expand Search), fid decreased (Expand Search), we decrease (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
Showing 81 - 100 results of 78,130 for search '(( significant ((side decrease) OR (step decrease)) ) OR ( significant compared diseases ))', query time: 1.29s Refine Results
  1. 81
    Changes from baseline to 12 weeks across all physiologic metrics.

    Changes from baseline to 12 weeks across all physiologic metrics. by Christopher Angelillo (17743121)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  2. 82
    Compare soft tissues relapses in patients with and without significant skeletal relapse.

    Compare soft tissues relapses in patients with and without significant skeletal relapse. by Sirada Chaisiri (17357163)

    Published 2023
    Save to List
    Saved in:
  3. 83
    CONSORT flow diagram.

    CONSORT flow diagram. by Christopher Angelillo (17743121)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  4. 84
    Inotodiol decreases clone formation in HCC cells.

    Inotodiol decreases clone formation in HCC cells. by Yushuang Xing (20636685)

    Published 2025
    “…Chemicals and chemotherapeutic agents have been experiencing problems such as side effects and drug resistance in the treatment of HCC, which cannot meet the needs of clinical treatment. …”
    Save to List
    Saved in:
  5. 85
    Inotodiol decreases clone formation in HCC cells.

    Inotodiol decreases clone formation in HCC cells. by Yushuang Xing (20636685)

    Published 2025
    Save to List
    Saved in:
  6. 86
    The trend of bilirubin levels of all, intervention, and control groups from baseline to discharge.

    The trend of bilirubin levels of all, intervention, and control groups from baseline to discharge. by Marjaneh Zarkesh (17621683)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  7. 87
    Flow chart of participants.

    Flow chart of participants. by Marjaneh Zarkesh (17621683)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  8. 88
    Data set: Dr aghili–analysis.

    Data set: Dr aghili–analysis. by Marjaneh Zarkesh (17621683)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  9. 89
    Inter and intra group analyses of bilirubin level in 12, 24, and 48 hours after hospitalization.

    Inter and intra group analyses of bilirubin level in 12, 24, and 48 hours after hospitalization. by Marjaneh Zarkesh (17621683)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  10. 90
    Baseline demographic characteristics in the intervention and control groups.

    Baseline demographic characteristics in the intervention and control groups. by Marjaneh Zarkesh (17621683)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  11. 91
    Characteristics of patients who decreased their screen time by more than 60 minutes after the challenge.

    Characteristics of patients who decreased their screen time by more than 60 minutes after the challenge. by Annaëlle Le Steunf (19838110)

    Published 2024
    Save to List
    Saved in:
  12. 92
    Sensitivity analysis graph of FA(A) and ADC(B) values between the compressed and healthy sides of LDH patients.

    Sensitivity analysis graph of FA(A) and ADC(B) values between the compressed and healthy sides of LDH patients. by Nan Wang (21935)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  13. 93
    Proteins significantly altered in subjects with CAD compared with subjects without CAD.

    Proteins significantly altered in subjects with CAD compared with subjects without CAD. by Andreas Casselbrant (12219175)

    Published 2022
    Save to List
    Saved in:
  14. 94
    Summary of significant findings.

    Summary of significant findings. by Marianna Danielli (14134437)

    Published 2023
    Subjects:
    Save to List
    Saved in:
  15. 95
    Significant downregulated proteins in <i>cprS</i>-mutant compared with WT.

    Significant downregulated proteins in <i>cprS</i>-mutant compared with WT. by Yingjie Song (7505393)

    Published 2024
    Save to List
    Saved in:
  16. 96
    Different steps of the fabrication process.

    Different steps of the fabrication process. by Md. Abu Daud (21485629)

    Published 2025
    Save to List
    Saved in:
  17. 97
    Transition probabilities and class sizes for three-step LTA model (N = 432).

    Transition probabilities and class sizes for three-step LTA model (N = 432). by Carolin Oetzmann (11397968)

    Published 2025
    Save to List
    Saved in:
  18. 98
    Statistical parametric mapping (<i>t</i>) intensity projection maps showing areas of significant decreases of grey matter volume (color code, yellow to orange) in a cohort of people with multiple sclerosis compared to healthy control subjects at baseline rendered on to a stereotactically normalized MRI scan in MNI space (z = -26 and -5; x = 46).

    Statistical parametric mapping (<i>t</i>) intensity projection maps showing areas of significant decreases of grey matter volume (color code, yellow to orange) in a cohort of peopl... by Rainer Ehling (89553)

    Published 2019
    Save to List
    Saved in:
  19. 99
    Neuropsychiatric performance in Fabry disease compared to healthy controls.

    Neuropsychiatric performance in Fabry disease compared to healthy controls. by Jacob W. Johnson (20172850)

    Published 2025
    Subjects: “…became statistically significant…”
    Save to List
    Saved in:
  20. 100
    Diseases excluded from the analysis.

    Diseases excluded from the analysis. by Rieko Kondo (10010647)

    Published 2022
    Subjects:
    Save to List
    Saved in:

Search Tools: